Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Sotagliflozin improves kidney function in type 1 diabetes
Last updated September 9, 2026
Key finding
Sotagliflozin increased copeptin levels by 33% (p < 0.01).
The study investigated the effects of sotagliflozin on copeptin levels and kidney injury in participants with type 1 diabetes, finding significant increases in copeptin and reductions in kidney injury markers.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
The study investigated the effects of sotagliflozin on copeptin levels and kidney injury in participants with type 1 diabetes, finding significant increases in copeptin and reductions in kidney injury markers.
Clinical relevance
These findings are clinically significant as they suggest that sotagliflozin may provide protective effects against kidney injury in patients with type 1 diabetes. Given the high risk of kidney complications in this population, the ability to improve kidney health through pharmacological intervention could lead to better long-term outcomes and quality of life for patients.
Keep in mind
The study's sample size may limit the generalizability of the findings. Long-term effects of sotagliflozin on kidney health were not assessed. The study did not include a diverse population, which may affect applicability.
Published in
Journal Reference
Publication details and source links for this paper.
Massimo N, Erik M, Hiddo JLH, et al. Sotagliflozin Increases Copeptin and Reduces Kidney Injury in Type 1 Diabetes. Diabetes, Obesity & Metabolism. 2026;28(4):3254-3263. doi:10.1111/dom.70520
Main Effects
Sotagliflozin increased copeptin levels by 33% (p < 0.01).
Urinary kidney injury molecule-1 (KIM-1) decreased by 19% (p = 0.03).
Sotagliflozin increased fractional excretion of glucose by 60-fold (p < 0.01).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Sotagliflozin and Copeptin, Fractional Excretion of Glucose (FE Glucose), Fractional Excretion of Lithium (FE Li), and 5 more.
This study contributes evidence to
Primary intervention
Sotagliflozin
Primary outcomes
- Copeptin
- Fractional Excretion of Glucose (FE Glucose)
- Fractional Excretion of Lithium (FE Li)
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
0
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 54
0
Related topics
8
Evidence pairs
0
Related studies
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 0 direct semantic evidence topics
Core evidence
Study findings
The primary outcomes reported in this study.
Fractional Excretion of Glucose (FE Glucose)
Sotagliflozin → Fractional Excretion of Glucose (FE Glucose)
Sotagliflozin → Fractional Excretion of Glucose (FE Glucose)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFractional Excretion of Lithium (FE Li)
Sotagliflozin → Fractional Excretion of Lithium (FE Li)
Sotagliflozin → Fractional Excretion of Lithium (FE Li)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerUrinary Kidney Injury Molecule-1 (KIM-1)
Sotagliflozin → Urinary Kidney Injury Molecule-1 (KIM-1)
Sotagliflozin → Urinary Kidney Injury Molecule-1 (KIM-1)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Copeptin levels increased by 33% with sotagliflozin (p < 0.01).
- Urinary KIM-1 decreased by 19%, indicating reduced kidney injury (p = 0.03).
- FE glucose increased by 60-fold, showing enhanced glucose excretion (p < 0.01).
Who this applies to
- Individuals diagnosed with type 1 diabetes.
- Patients at risk for kidney injury due to diabetes.
Keep in Mind
- Results may not be applicable to populations outside the study's demographics.
- The study did not evaluate the long-term impact of sotagliflozin.
- Further research is needed to confirm these findings in larger, more diverse cohorts.
Between the Lines
- The study's sample size may limit the generalizability of the findings.
- Long-term effects of sotagliflozin on kidney health were not assessed.
- The study did not include a diverse population, which may affect applicability.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Sotagliflozin and Copeptin, Sotagliflozin and Fractional Excretion of Glucose (FE Glucose).
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Sotagliflozin → Copeptin
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Copeptin Evidence Hub
All studies measuring Copeptin
1 studies
outcome_hubMeasures Copeptin as a key outcome.
Fractional Excretion of Glucose (FE Glucose) Evidence Hub
All studies measuring Fractional Excretion of Glucose (FE Glucose)
1 studies
outcome_hubMeasures Fractional Excretion of Glucose (FE Glucose) as a key outcome.
Sotagliflozin Evidence Hub
All studies on Sotagliflozin
1 studies
intervention_hubContributes to Sotagliflozin evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Sotagliflozin and Copeptin
Intervention: SotagliflozinOutcome: Copeptin
1 results
All studies on Sotagliflozin and Fractional Excretion of Glucose (FE Glucose)
Intervention: SotagliflozinOutcome: Fractional Excretion of Glucose (FE Glucose)
1 results
All studies on Sotagliflozin
Intervention: Sotagliflozin
1 results
All studies measuring Copeptin
Outcome: Copeptin
1 results
All studies measuring Fractional Excretion of Glucose (FE Glucose)
Outcome: Fractional Excretion of Glucose (FE Glucose)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Sotagliflozin improve copeptin?
Emerging Evidence
Sotagliflozin appears to improve copeptin.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Copeptin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Sotagliflozin improve fractional excretion of glucose (fe glucose)?
Emerging Evidence
Sotagliflozin appears to improve fractional excretion of glucose (fe glucose).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fractional Excretion of Glucose (FE Glucose)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Sotagliflozin improve fractional excretion of lithium (fe li)?
Emerging Evidence
Sotagliflozin appears to improve fractional excretion of lithium (fe li).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Fractional Excretion of Lithium (FE Li)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Sotagliflozin improve hemoglobin?
Emerging Evidence
Sotagliflozin appears to improve hemoglobin.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Hemoglobin
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Empagliflozin improves heart function in type 2 diabetes patientsGlutamine supplementation may decrease glycaemia in type 2 diabetes.CPAP treatment reduces aldosterone levels in diabetes and sleep apneaCalcitriol may reduce kidney injury in early diabetic kidney diseaseDapagliflozin may improve RAAS markers in diabetes patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.